FierceBiotech8h
GSK scratches itch for phase 3 win, hitting goal in liver disease trial to open up untapped market
A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...
pharmaphorum4h
GSK drug raises hopes for patients with PBC itch
Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...
GSK drug meets main goal in late-stage study to treat relentless itch
British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...
The Pharma Letter2h
Linerixibat shows positive Phase III results in PBC, says GSK
UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...
GSK's linerixibat meets primary endpoint
Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...
MedPage Today16h
'Stop RFK War Room'; Trump Overhauling Medicaid? Why Assaults at Hospitals Rose
Investigational linerixibat showed positive phase III results in cholestatic pruritus associated with primary biliary ...
pharmaphorum9h
Grifols linked to €7bn takeover offer from Brookfield
Grifols is anticipating a period of strong growth on the back of its recently FDA-approved intravenous immunoglobulin product ...